Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Anthony DohanBenoit GallixBoris GuiuKarine Le MalicotCaroline ReinholdPhilippe SoyerJaafar BennounaFrancois GhiringhelliEmilie BarbierValérie BoigeJulien TaiebOlivier BouchéEric FrançoisJean-Marc PhelipChristian BorelRoger FarouxJean-Francois SeitzStéphane JacquotMeher Ben AbdelghaniFaiza Khemissa-AkouzDominique GenetJean Louis JouveYves RinaldiFrançoise DesseignePatrick TexereauEtienne SucCome LepageThomas AparicioChristine Hoeffelnull nullPublished in: Gut (2019)
Clinicaltrial.gov identifier of the PRODIGE 9 study: NCT00952029.Clinicaltrial.gov identifier of the PRODIGE 20 study: NCT01900717.
Keyphrases